UDOCF (UniDoc Health) 3-Year RORE % : -17.32% (As of Dec. 2025)


What is UniDoc Health 3-Year RORE %?

UniDoc Health UDOCF -11.04% 3-Year RORE % is -17.32 as of Dec. 2025. The stock has 4 warning signs investors should review. Among 605 Healthcare Providers & Services companies, UniDoc Health ranks worse than 64.79% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. UniDoc Health's 3-Year RORE % for the quarter that ended in Dec. 2025 was -17.32%.

The industry rank for UniDoc Health's 3-Year RORE % or its related term are showing as below:

UDOCF's 3-Year RORE % is ranked worse than
64.79% of 605 companies
in the Healthcare Providers & Services industry
Industry Median: 0.38 vs UDOCF: -17.32

UniDoc Health  (OTCPK:UDOCF) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


UniDoc Health 3-Year RORE % Related Terms


UniDoc Health 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for UniDoc Health's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UniDoc Health 3-Year RORE % Chart

UniDoc Health Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
3-Year RORE %
0.00 0.00 0.00 -36.65 16.15

UniDoc Health Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.46 16.15 -2.73 -13.41 -17.32

UDOCF vs VEEV, BTSG, TEM: 3-Year RORE % Comparison

For the Health Information Services subindustry, UniDoc Health's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


UniDoc Health 3-Year RORE % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, UniDoc Health's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where UniDoc Health's 3-Year RORE % falls into.



UniDoc Health 3-Year RORE % Calculation

UniDoc Health's 3-Year RORE % for the quarter that ended in Dec. 2025 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.028--0.059 )/( -0.179-0 )
=0.031/-0.179
=-17.32 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -17.32 mean?
UniDoc Health (UDOCF) has a 3-Year RORE % of -17.32 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on UniDoc Health and its competitors. According to the industry distribution chart, UniDoc Health ranks #392 out of 605 companies in the Healthcare Providers & Services industry, placing it in the top 64.8%.
Is UniDoc Health's 3-Year RORE % too high?
UniDoc Health's current 3-Year RORE % is -17.32. Based on the distribution chart, UniDoc Health ranks #392 out of 605 companies in the Healthcare Providers & Services industry, which is below the industry midpoint.
How does UniDoc Health's 3-Year RORE % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, UniDoc Health ranks #392 out of 605 companies for 3-Year RORE %. This places UniDoc Health in the lower half of its industry. The industry median 3-Year RORE % is 0.38. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Healthcare Providers & Services company?
The median 3-Year RORE % among Healthcare Providers & Services companies is 0.38, based on 605 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on UniDoc Health and its competitors. For the Healthcare Providers & Services industry, the median 3-Year RORE % is 0.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. UniDoc Health's current 3-Year RORE % is -17.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UniDoc Health stock overvalued right now?
UniDoc Health (UDOCF) has a current 3-Year RORE % of -17.32. The current 3-Year RORE % is -17.32. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For UniDoc Health (UDOCF), the current 3-Year RORE % is -17.32 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

UniDoc Health Business Description

Other Exchanges L7T:GermanyUDOC:Canada
Address Unit 18, 81 Zenway Boulevard, Woodbridge, ON, CAN, L4H 0S5
UniDoc Health Corp operates in the healthcare services industry and plans to operate telehealth units that contain fully integrated diagnostic tools and will provide patients with the ability to have a live virtual visit with a doctor or other health professional. The company operates in the USA and Canada.